hVIVO plc (LON:HVO - Get Free Report)'s stock price was up 19.3% on Monday . The stock traded as high as GBX 11 ($0.15) and last traded at GBX 10.38 ($0.14). Approximately 42,482,375 shares traded hands during mid-day trading, an increase of 1,018% from the average daily volume of 3,800,164 shares. The stock had previously closed at GBX 8.70 ($0.12).
Analysts Set New Price Targets
Separately, Shore Capital reaffirmed a "buy" rating on shares of hVIVO in a research note on Friday.
View Our Latest Analysis on HVO
hVIVO Stock Performance
The stock's 50-day simple moving average is GBX 16.08 and its 200 day simple moving average is GBX 17.93. The company has a debt-to-equity ratio of 33.86, a quick ratio of 1.16 and a current ratio of 1.61. The company has a market capitalization of £73.59 million, a PE ratio of 4.29 and a beta of 0.97.
hVIVO (LON:HVO - Get Free Report) last released its earnings results on Thursday, April 10th. The company reported GBX 1.69 ($0.02) EPS for the quarter. hVIVO had a net margin of 25.96% and a return on equity of 47.93%. As a group, research analysts expect that hVIVO plc will post 1.5492958 earnings per share for the current fiscal year.
Insider Transactions at hVIVO
In related news, insider Yamin Mo' Khan sold 3,062,246 shares of the business's stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of GBX 17 ($0.23), for a total value of £520,581.82 ($703,774.26). Insiders own 14.03% of the company's stock.
About hVIVO
(
Get Free Report)
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.
Further Reading
Before you consider hVIVO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and hVIVO wasn't on the list.
While hVIVO currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
